Appendix 3X – Kit Wei Lui – March 2019
Appendix 3X
ASX Announcements
Board Changes – March 2019
Board Changes
Cleansing Statement – March 2019
Cleaning Statement
Appendix 3B – March 2019
Appendix 3B
Appendix 4D – Half Yearly Report and Accounts
Appendix 4D – Half Yearly Report and Accounts
Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant
EXCERPT: February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an …
Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng
EXCERPT: February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system …
Quarterly Appendix 4C and Business updates
Quarterly Appendix 4C and Business updates
IVQ technology development agreement with SIBCB on breast cancer.
EXCERPT: January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDO® …
Invitrocue roll-out of Onco-PDO services in Germany
EXCERPT: “We are pleased to establish Invitrocue’s first laboratory in Europe, quickly expanding the availability of Onco-PDO® to a much wider patient and physician group. Approximately one quarter of the global total of cancer cases are in Europe with some 3.7 million new patients a year. Our collaboration with Systasy enables us to deliver against …